Prática challenge of the management of covid-19 in patients with obesity

Ana Beatriz Costa; Bruno de Andrade Marquetto; Isabela Rosendo Mendonça; Fabiana Schuelter-Trevisol; Gislaine Tezza Rezin

Ana Beatriz Costa UNISUL
Bruno de Andrade Marquetto Medical Course, University of South Santa Catarina, Tubarão-SC, Brazil.
Isabela Rosendo Mendonça Medical Course, University of South Santa Catarina, Tubarão-SC, Brazil.
Fabiana Schuelter-Trevisol Graduate Program in Health Sciences, University of South Santa Catarina, Tubarão, SC, Brazil. Hospital Nossa Senhora da Conceição Clinical Research Center, Tubarão-SC, Brazil.
Gislaine Tezza Rezin Laboratory of Neurobiology of Inﬂammatory and Metabolic Processes, Graduate Program in Health Sciences, Health Sciences Unit, University of South Santa Catarina, Tubarão-SC, Brazil.

Palavras-chave: Endocrinologia, Infecções por Coronavirus, Manejo da Obesidade, Conduta do Tratamento Medicamentoso

Resumo

A obesidade é uma condição associada a piores desfechos de pacientes infectados com o coronavirus da síndrome respiratória aguda grave 2 (SARS-CoV-2). Está ligada a disfunções endócrinas e imunológicas, tornando o paciente mais vulnerável à doença causada pelo vírus. Considerando que os mecanismos fisiopatológicos envolvidos na doença por coronavírus - 2019 (COVID-19) causada pelo SARS-CoV-2 ainda não são claros, a busca por diversos fármacos para o tratamento ou prevenção da doença ainda está em andamento. Portanto, é fundamental revisar os mecanismos de ação dos fármacos sobre a COVID-19 grave e sua interação farmacológica com a obesidade.

Referências

-Abduljabbar, T.; Al-Sahaly, F.; Kellesarian, S.V.; Kellesarian, T.V.; Al-Anazi, M.; Al-Khathami, M.; Javed, F.; Vohra, F. Comparison of peri-implant clinical and radiographic inflammatory parameters and whole salivary destructive inflammatory cytokine profile among obese and non-obese men. Cytokine. Vol. 88. 2016. p. 51-56.

-Anjos, L.A. Diagnosis of obesity and determination of nutritional requirements: Challenges for the area of nutrition. Cienc e Saude Coletiva. Vol. 18. Num. 295. 2013.

-Al-Tawfiq, J.A.; Al-Homoud, A.H.; Memish, Z.A. Remdesivir as a possible therapeutic option for the COVID-19. Travel Med Infect Dis. Vol. 34. 2020. 101615.

-Atallah, B.; Mallah, S.I.; AlMahmeed, W. Anticoagulation in COVID-19. Eur Heart J. Vol. 6. 2020. p. 260-261.

-Atri, D.; Siddiqi, H.K.; Lang, J.P.; Nauffal, V.; Morrow, D.A.; Bohula, E.A. COVID-19 for the Cardiologist: Basic Virology, Epidemiology, Cardiac Manifestations, and Potential Therapeutic Strategies. JACC Basic to Transl Sci. Vol. 5. 2020. p. 518-536.

-Badimon, L.; Cubedo, J. Adipose tissue depots and inflammation: Effects on plasticity and residentmesenchymal stem cell function. Cardiovasc Res. Vol. 113. 2017. p. 1064-1073.

-Badimon, L.; Vera, R.H.; Padró, T.; Vilahur, G. Antithrombotic therapy in obesity. Researchgate. Vol. 110. 2013. p. 681-688.

-Beigel, J.H.; Tomashek, J.M.; Dodd, L.E.; Mehta, A.K.; Zingman, B.S.; Kalil, A.C.; Hohmann, E.; Chu, H.Y.; Luetkemeyer, A.; Kline, S.; Lopez de Castilla, D.; Finberg, R.W. Remdesivir for the Treatment of Covid-19. N Engl J Med. Vol. 383. 2020. p. 1813-1826.

-Bollinger, T.; Gies, S.; Naujoks, J.; Feldhoff, L.; Bollinger, A.; Solbach, W.; Rupp J. HIF-1 - and hypoxia-dependent immune responses in human CD4+CD25high T cells and T helper 17 cells. J Leukoc Biol. Vol. 96. 2014. p. 305-312.

-Bucher Della Torre, S.; Courvoisier, D.S.; Saldarriaga, A.; Martin, X.E.; Farpour-Lambert, N.J. Knowledge, attitudes, representations and declared practices of nurses and physicians about obesity in a university hospital: training is essential. Clin Obes. Vol. 8. 2018. p. 122-130.

-Caesar, G. Declaração de pandemia, voos e vistos cancelados: veja números da volta de brasileiros do exterior. 2020. https://g1.globo.com/mundo/noticia/2020/05/02/declaracao-de-pandemia-voos-e-vistos-cancelados-veja-numeros-da-volta-de-brasileiros-do-exterior.ghtml. 2020. accessed 28/07/2020.

-Cao, B.; Wang, Y.; Wen, D.; Liu, W.; Wang, J.; Fan, G.; Ruan, L.; Song, B.; Cai, Y.; Wei, M.; Li, X. A trial of lopinavir-ritonavir in adults hospitalized with severe covid-19. N Engl J Med. Vol. 382. 2020. p. 1787-1799.

-Castoldi, A.; Souza, C.N.; Saraiva Câmara, N.O.; Moraes-Vieira, P.M. The macrophage switch in obesity development. Front Immunol. Vol. 6. 2016.

-Chade J. OMS classifica coronavirus como pandemia e cobra ação dos governos. 2020. https://noticias.uol.com.br/colunas/jamil-chade/2020/03/11/proliferacao-de-coronavirus-leva-oms-a-declarar-pandemia.htm. 2020. accessed 28/07/2020.

-Darvall, K.A.L.; Sam, R.C.; Silverman, S.H.; Bradbury, A.W.; Adam, D.J. Obesity and Thrombosis. Eur J Vasc Endovasc Surg. Vol. 33. 2006. p. 223-233.

-De Jong, A.; Chanques, G.; Jaber, S. Mechanical ventilation in obese ICU patients: From intubation to extubation. Crit Care. Vol. 21. 2017.

-Dietz, W.; Santos-Burgoa, C. Obesity and its Implications for COVID-19 Mortality. Obesity. Vol. 28. Num. 1005. 2020.

-Eichinger, S.; Hron, G.; Bialonczyk, C.; Hirschl, M.; Minar, E.; Wagner, O.; Heinze, G.; Kyrle, P.A. Overweight, Obesity, and the Risk of Recurrent Venous Thromboembolism. Thromb Haemost. Vol. 168. 2008. p. 1678-1683.

-Food and drug administration. FDA Newa Release. FDA Approves First Treatment for COVID-19. https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-covid-19. 2020. accessed 21/12/2020.

-Galic, S.; Oakhill, J.S.; Steinberg, G.R. Molecular and Cellular Endocrinology Adipose tissue as an endocrine organ. Mol Cell Endocrinol. Vol. 316. 2010. p. 129-139.

-Gbinigie, K.; Frie, K. Should azithromycin be used to treat COVID-19? A rapid review. BJGP Open. Vol. 4. 2020.

-Guo, Y.R.; Cao, D.Q.; Hong, Z.S.; Tan, Y.Y.; Chen, S.D.; Jin, H.J.; Tan, K.S.; Wang, D.Y.; Yan, Y. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status. Mil Med Res. Vol. 7. 2020.

-Gupta, R.; Misra, A. Contentious issues and evolving concepts in the clinical presentation and management of patients with COVID-19 infectionwith reference to use of therapeutic and other drugs used in Co-morbid diseases (Hypertension, diabetes etc). Diabetes Metab Syndr Clin Res Rev. Vol. 14. 2020. p. 251-254.

-Hajifathalian, K.; Kumar, S.; Newberry, C.; Shah, S.; Fortune, B.; Krisko, T.; Ortiz-Pujols, S.; Zhou, X.K.; Dannenberg, A.J.; Kumar, R.; Sharaiha, R.Z. Obesity is Associated with Worse Outcomes in COVID-19: Analysis of Early Data from New York City. Obesity. Vol. 28. 2020. p.1606-1612.

-Horby, P.A.; Mafham, M.; Linsell, L.; Bell, J.L.; Staplin, N.; Emberson, J.R.; Wiselka, M.; Ustianowski, A. Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19. N Engl J Med. Vol. 383. 2020. p. 2030-2040.

-Jia, X.; Yin, C.; Lu, S.; Chen, Y.; Liu, Q.; Bai, J.; Lu, Y. Two Things About COVID-19 Might Need Attention. Preprints. Vol. 2. 2020.

-Jin, Y.; Yang, H.; Ji, W.; Wu, W.; Chen, S.; Zhang, W.; Duan, G. Virology, Epidemiology, Pathogenesis, and Control of COVID-19. Viruses. Vol. 12. 2020. p. 372-489.

-John, K.; Marino, J.S.; Sanchez, E.R.; Hinds, T.D. The glucocorticoid receptor: Cause of or cure for obesity?. Am J Physiol - Endocrinol Metab. Vol. 310. 2016. p. 249-257.

-Johnson, A.R.; Justin Milner, J.; Makowski, L. The inflammation highway: metabolism accelerates inflammatory traffic in obesity. Immunol Rev. Vol. 249. 2012. p. 218-238.

-Jorgensen, S.C.J.; Kebriaei, R.; Dresser, L.D. Remdesivir: Review of pharmacology, pre-clinical data and emerging clinical experience for COVID-19. Pharmacotherapy. Vol. 40. 2020. p. 659-671.

-Kalligeros, M.; Shehadeh, F.; Mylona, E.K.; Benitez, G.; Beckwith, C.G.; Chan, P.A.; Mylonakis, E. Association of Obesity with Disease Severity Among Patients with Coronavirus Disease 2019. Obesity. Vol. 28. 2020. p. 1200-1204.

-Kaur, J. A comprehensive review on metabolic syndrome. Cardiol Res Pract. 2014.

-Kruglikov, I.L.; Scherer, P.E.The Role of Adipocytes and Adipocyte-Like Cells in the Severity of COVID-19 Infections. Obesity. Vol. 28. 2020. p. 1187-1190.

-Kumar, R.; Gupta, N.; Kodan, P.; Mittal, A.; Soneja, M.; Wig, N. Battling COVID-19: using old weapons for a new enemy. Trop Dis Travel Med Vaccines. Vol. 6. 2020.

-Lai; C.C.; Shih, T.P.; Ko, W.C.; Tang, H.J.; Hsueh, P.R. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int J Antimicrob Agents. Vol. 55. 2020.

-Li, B.; Yang, J.; Zhao, F.; Zhi, L.; Wang, X.; Liu, L.; Bi, Z.; Zhao, Y. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol. Vol. 109. 2020. p. 531-538.

-Li, R.; Wang, H.; Shi, Q.; Wang, N.; Zhang, Z.; Xiong, C.; Liu, J.; Chen, Y.; Jiang, L.; Jiang, Q. Effects of oral florfenicol and azithromycin on gut microbiota and adipogenesis in mice. PLoS One. Vol. 12. 2017.

-Li, Y.N.; Su, Y. Remdesivir attenuates high fat diet (HFD)-induced NAFLD by regulating hepatocyte dyslipidemia and inflammation via the suppression of STING. Biochem Biophys Res Commun. Vol. 526. 2020. p. 381-388.

-Lighter, J.A.; Phillips, M.; Hochman, S.; Sterling, S.; Johnson, D.; Francois, F.; Stachel, A. Obesity in patients younger than 60 years is a risk factor for Covid-19 hospital admission. Clin Infect Dis. Vol. 71. Num. 15. 2020. p. 896-897.

-Lindahl, S.G.E. Using the prone position could help to combat the development of fast hypoxia in some patients with COVID-19. Acta Paediatr Int J Paediatr. Vol. 109. 2020. p. 1539-1544.

-Luzi, L.; Radaelli, M.G. Influenza and obesity: its odd relationship and the lessons for COVID-19 pandemic. Acta Diabetol. Vol. 57. 2020. p. 759-764.

-Maury, E.; Brichard, S.M. Adipokine dysregulation, adipose tissue inflammation and metabolic syndrome. Mol Cell Endocrinol. Vol. 314. 2010.

-McSharry, D.; Malhotra, A. Potential influences of obstructive sleep apnea and obesity on COVID-19 severity. J Clin Sleep Med. Vol. 16. 2020. p. 1645.

-Michailidou, Z. Fundamental roles for hypoxia signalling in adipose tissue metabolism and inflammation in obesity. Curr Opin Physiol. Vol. 12. 2019. p. 39-43.

-Morange, P.; Alessi, M. Thrombosis in central obesity and metabolic syndrome : Mechanisms and epidemiology. Thromb Haemost. Vol. 110. 2013. p. 669-680.

-Muscogiuri, G.; Pugliese, G.; Barrea, L.; Savastano, S.; Colao, A. Obesity: The “Achilles heel” for COVID-19?. Metabolism. Vol. 108. 2020.

-Noppe, G.; Van Den Akker, E.L.T.; De Rijke, Y.B.; Koper, J.W.; Jaddoe, V.W.; Van Rossum, E.F.C. Long-term glucocorticoid concentrations as a risk factor for childhood obesity and adverse body-fat distribution. Int J Obes. Vol. 40. 2016. p. 1503-1509.

-Ohashi, K.; Shibata, R.; Murohara, T.; Ouchi, N. Role of anti-inflammatory adipokines in obesity-related diseases. Trends Endocrinol Metab. Vol. 25. 2014. p. 348-355.

-Pan-American Health Organization. Therefore, Dexamethasone Is Curr. Part Treat. Protoc. Patients Infected with SARS-CoV-2 a Moderate to Sev. State. https://www.paho.org/pt/covid19. 2020. accessed 21/12/2020.

-Paredes, S.; Alves, M. Abordagem e tratamento da hiperglicemia induzida por glicocorticóides. Acta Med Port. Vol. 29. 2016. p. 556-563.

-Park, H.S.; Park, J.Y.; Yu, R. Relationship of obesity and visceral adiposity with serum concentrations of CRP, TNF-α and IL-6. Diabetes Res Clin Pract. Vol. 69. 2005. p. 29–35.

-Pepperrell, T.; Pilkington, V.; Owen, A.; Wang, J.; Hill, A.M. Review of safety and minimum pricing of nitazoxanide for potential treatment of COVID-19. J Virus Erad. Vol. 6. 2020. p. 52-60.

-Recovery Collaborative Group. Effect of Dexamethasone in Hospitalized Patients with COVID-19 - Preliminary Report. Oxford Univ. News Release. 2020.

-Rosito, G.A.; Agostino, R.B.D.; Massaro, J.; Lipinska, I.; Mittleman, M.A.; Sutherland, P.; Wilson, P.W.F.; Levy, D.; Muller, J.E.; Tofler, G.H. Association between obesity and a prothrombotic state : the Framingham Offspring Study. Thromb Haemost. Vol. 91. 2004. p. 683-689.

-Ryan, P.M.D.; Caplice, N.M. Is Adipose Tissue a Reservoir for Viral Spread, Immune Activation, and Cytokine Amplification in Coronavirus Disease 2019?. Obesity. Vol. 28. 2020. p. 1191-1194.

-Santos, W.G. Natural history of COVID-19 and current knowledge on treatment therapeutic options. Elsevier Masson SAS. 2020.

-Salazar-Sepúlveda, L.L.; Villarreal-Pérez, J.Z. Impact of diagnosis of overweight and obesity on weight management among hospitalized patients. Obes Res Clin Pract. Vol. 13. 2019. p. 164-167.

-Selim, B.J.; Ramar, K.; Surani, S. Obesity in the intensive care unit: risks and complications. Hosp Pract. Vol. 44. 2016. p. 146-156.

-Selvaraj, V.; Dapaah-afriyie, K.; Finn, A.; Flanigan, T.P. Short-Term Dexamethasone in Sars-CoV-2 Patients. R I Med J. Vol. 103. 2020. p. 39-43.

-Shi, C.; Wang, C.; Wang, H.; Yang, C.; Cai, F.; Zeng, F.; Cheng, F.; Liu, Y. The potential of low molecular weight heparin to mitigate cytokine storm in severe COVID-19 patients : a retrospective clinical study. MedRxiv. Vol. 13. 2020. p. 1087-95.

-Simonnet, A.; Chetboun, M.; Poissy, J.; Raverdy, V.; Noulette, J.; Duhamel, J.; Julien Labreuche, J.; Mathieu, D.; Pattou, F.; Jourdain, M. High Prevalence of Obesity in Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Requiring Invasive Mechanical Ventilation. Obesity. Vol. 28. 2020. p. 1195-1199.

-Singh, A.K.; Majumdar, S.; Singh, R.; Misra, A. Role of corticosteroid in the management of COVID-19: A systemic review and a Clinician’s perspective. Diabetes Metab Syndr Clin Res Rev. Vol. 14. 2020. p.971-978.

-Skipper, C.P.; Pastick, K.A.; Engen, N.W.; Bangdiwala, A.S.; Abassi, M.; Lofgren, S.M.; Williams, D.A.; Okafor, E.C.; Pullen, M.F. Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19 : A Randomized Trial. Ann Intern Med. Vol. 173. 2020. p. 623-631.

-Solinas, C.; Perra, L.; Aiello, M.; Migliori, E.; Petrosillo, N. A critical evaluation of glucocorticoids in the treatment of severe COVID-19. Cytokine Growth Factor Rev. Vol. 54. 2020. p. 8-23.

-Spinner, C.D.; Gottlieb, R.L.; Criner, G.D.; Arribas López, J.R.; Cattelan, A.M.; Soriano Viladomiu, A.; Ogbuagu, O.; Malhotra, P.; Mullane, K.M.; Castagna, A.; Chai, L.Y.A. Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients with Moderate COVID-19: A Randomized Clinical Trial. JAMA - J Am Med Assoc. Vol. 324. 2020. p. 1048-1057.

-Sun, J.K.; Chen, Y.T.; De Fan, X.; Wang, X.Y.; Han, Q.Y.; Liu, Z.W. Advances in the use of chloroquine and hydroxychloroquine for the treatment of COVID-19. Postgrad Med. Vol. 132. 2020. p. 604-613.

-Tamez-Pérez, H.E. Steroid hyperglycemia: Prevalence, early detection and therapeutic recommendations: A narrative review. World J Diabetes. Vol. 6. 2015.

-Tang, N.; Bai, H.; Chen, X.; Gong, J.; Li, D.; Sun, Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. Vol. 18. 2020. p. 1094-1099.

-Tchernof, A.; Després, J.P. Pathophysiology of human visceral obesity: An update. Physiol Rev. Vol. 93. 2019. p. 359-404.

-Thompson-Moore, N.R.; Wanat, M.A.; Putney, D.R.; Liebl, P.H.N.; Chandler, W.L.; 71-Muntz, J.E. Evaluation and Pharmacokinetics of Treatment Dose Enoxaparin in Hospitalized Patients with Morbid Obesity. Clin Appl Thromb. Vol. 21. 2015.513-520.

-Trayhurn, P. Hypoxia and adipose tissue function and dysfunction in obesity. Physiol Rev. Vol. 93. 2013.

-Vandiver, J.W.; Ritz, L.I.; Lalama, J.T. Chemical prophylaxis to prevent venous thromboembolism in morbid obesity: literature review and dosing recommendations. J Thromb Thrombolysis. Vol. 41. 2016. p. 475–481.

-Wang, T.; Milligan, P.E.; Wong, C.A.; Deal, E.N.; Thoelke, M.S. HHS Public Access. Thromb Haemost. Vol. 111. 2015. p. 88-93.

-Wang, Y.; Zhang, D.; Du, G.; Du, R.; Zhao, J.; Jin, Y.; Fu, S.; Gao, L.; Cheng, Z.; Lu, Q.; Hu, Y.; Luo, G.; Wang, K. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. Vol. 395. 2020. p. 1569-1578.

-Weghuber, D.; Mangge, H.; Hochbrugger, E.; Stulnig, T.M. Impact of age and metabolic syndrome on the adipokine profile in childhood and adult obesity. Exp Clin Endocrinol Diabetes. Vol. 122. 2014. p. 363-367.

-Westendorf, A.M.; Skibbe, K.; Adamczyk, A.; Buer, J.; Geffers, R.; Hansen, W.; Pastille, E.; Jendrossek, V. Hypoxia enhances immunosuppression by inhibiting CD4+ Effector T cell function and promoting treg activity. Cell Physiol Biochem. Vol. 41. 2017. p. 1271-1284.

-Williams, E.P.; Mesidor, M.; Winters, K.; Dubbert, P.M.; Wyatt, S.B. Overweight and Obesity: Prevalence, Consequences, and Causes of a Growing Public Health Problem. Curr Obes Rep. Vol 4. 2015. p.363-370.

-Word Health Obesity. Obesity. https://www.who.int/health-topics/obesity#tab=tab_1. 2020. accessed 21/12/2020.

-Word Obesity. About obesity. https://www.worldobesity.org/about/about-obesity. 2020. accessed 28/07/2020.

-World Health Organization. Obesity and overwheight. Obes Overwheight. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight. 2020. accessed 21/12/2020.

-Wu, C.; Chen, X.; Cai, Y.; Xia, J.; Zhou, X.; Xu, S.; Huang, H.; Zhang, L.; Zhou, X.; Du, C.; Zhang, Y. Risk Factors Associated with Acute Respiratory Distress Syndrome and Death in Patients with Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med. Vol. 180. 2020. p.934-943.

-Xu, C.; Mathews, A.E.; Rodrigues, C.; Eudy, B.J.; Rowe, C.A.; O’Donoughue, A.; Percival, S.S. Aged garlic extract supplementation modifies inflammation and immunity of adults with obesity: A randomized, double-blind, placebo-controlled clinical trial. Clin Nutr ESPEN. Vol. 24. 2018. p. 148-155.

-Yang, Z.; Prinsen, J.K.; Bersell, K.R.; Shen, W.; Yermalitskaya, L.; Sidorova, T.; Luis, P.B.; Hall, L.; Zhang, W.; Du, L.; Milne, G.; Tucker, P.; George, A.L.; Campbell, C.M. Azithromycin Causes a Novel Proarrhythmic Syndrome. Circ Arrhythmia Electrophysiol. Vol. 10. 2017.

-Yates, T.; Razieh, C.; Zaccardi, F.; Davies, M.J.; Khunti, K. Obesity and risk of COVID-19: analysis of UK biobank. Prim Care Diabetes. Vol. 14. 2020. p. 566-567.

-Yuki, K.; Fujiogi, M.; Koutsogiannaki, S. COVID-19 pathophysiology: A review. Clin Immunol. Vol. 215. 2020.

-Zhang, A.J.X.; To, K.K.W.; Li, C.; Lau, C.C.Y.; Poon, V.K.M.; Chan, C.C.S.; Zheng, B.J.; Hung, I.F.N.; Lam, K.S.L.; Xu, A.; Yuen, K.Y. Leptin mediates the pathogenesis of severe 2009 pandemic influenza A(H1N1) infection associated with cytokine dysregulation in mice with diet-induced obesity. J Infect Dis. Vol. 207. 2013. p. 1270-1280.

-Zheng, K.I.; Gao, F.; Wang, X.B.; Sun, Q.F.; Pan, K.H.; Wang, T.Y.; Ma, H.L.; Liu, W.Y.; George, J.; Zheng, M.H. Obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease. Metabolism. Vol. 101. 2020. p.1-15.

-Zheng, Z.; Peng, F.; Xu B.; Zhao J, Liu H, Peng J, Li Q, Jiang C, Zhou Y, et al. Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis. J Infect. Vol. 81. 2020.16-25.

-Zhou, F.; Yu, T.; Du, R.; Fan, G.; Liu, Y.; Liu, Z.; Xiang, J.; Wang, Y.; Song, B.; Gu, X.; Guan, L.; Wei, Y. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. Vol. 395. 2020. p. 1054-1062.

-Zou, L.; Dai L.; Zhang, X.; Zhang, Z.; Zhang, Z. Hydroxychloroquine and chloroquine: a potential and controversial treatment for COVID-19. Arch Pharm Res. Vol 43. 2020. p. 765-772.

Desafio do manejo da covid-19 em pacientes com obesidade

Resumo

Referências